biloxiblues, BB, The company bluebird bio, Inc
Post# of 148110
The company bluebird bio, Inc (Ticker symbol - BLUE) has an FDA-approved gene therapy for sickle cell disease.
One of the downside risks is hematologic malignancy, and monitoring every six months is needed. The pricing is approx $2-3 million per patient. The company has negotiated payment agreements with the major government payers; I don't know those numbers.
I don't own BLUE and won't own it. I happened to see the announcement of FDA approval for a treatment of this horrible disease. The share price hardly budged with that announcement.